Literature DB >> 11549542

Recombinant human superoxide dismutase enhances the effect of inhaled nitric oxide in persistent pulmonary hypertension.

R H Steinhorn1, G Albert, D D Swartz, J A Russell, C R Levine, J M Davis.   

Abstract

We investigated the pulmonary vascular effects of superoxide dismutase (SOD) alone and in combination with inhaled nitric oxide (iNO) in newborn lambs with persistent pulmonary hypertension (PPHN) following prenatal ligation of the ductus arteriosus. In in vitro experiments, pretreatment with SOD significantly enhanced vascular relaxation in response to the NO donor S-nitrosyl-acetylpenicillamine (SNAP) in fifth-generation pulmonary arteries isolated from lambs with PPHN. In vivo treatment of fully instrumented newborn lambs with a single intratracheal dose of recombinant human CuZn SOD (rhSOD; 5 mg/kg) produced selective dilation of the pulmonary circulation. Further studies, of the combination of rhSOD and iNO, showed enhancement of the pulmonary vascular effects of iNO after brief periods of inhalation of 5 ppm and 80 ppm NO. We conclude that rhSOD reduces pulmonary vascular resistance and facilitates the action of iNO in a lamb model of PPHN. This suggests that rhSOD may prove to be an effective adjunctive treatment for newborns with PPHN.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549542     DOI: 10.1164/ajrccm.164.5.2010104

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  35 in total

1.  Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target.

Authors:  Stephen L Archer; Glenn Marsboom; Gene H Kim; Hannah J Zhang; Peter T Toth; Eric C Svensson; Jason R B Dyck; Mardi Gomberg-Maitland; Bernard Thébaud; Aliya N Husain; Nicole Cipriani; Jalees Rehman
Journal:  Circulation       Date:  2010-06-07       Impact factor: 29.690

Review 2.  Nitric oxide and beyond: new insights and therapies for pulmonary hypertension.

Authors:  R H Steinhorn
Journal:  J Perinatol       Date:  2008-12       Impact factor: 2.521

Review 3.  Bringing down the ROS: a new therapeutic approach for PPHN.

Authors:  Amy L Firth; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-10-17       Impact factor: 5.464

Review 4.  The role of genetic polymorphisms in antioxidant enzymes and potential antioxidant therapies in neonatal lung disease.

Authors:  Carlo Dani; Chiara Poggi
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

Review 5.  Therapies that enhance pulmonary vascular NO-signaling in the neonate.

Authors:  Julie Dillard; Marta Perez; Bernadette Chen
Journal:  Nitric Oxide       Date:  2019-12-20       Impact factor: 4.427

Review 6.  Neonatal pulmonary hypertension.

Authors:  Robin H Steinhorn
Journal:  Pediatr Crit Care Med       Date:  2010-03       Impact factor: 3.624

7.  Acute hypoxia simultaneously induces the expression of gp91phox and endothelial nitric oxide synthase in the porcine pulmonary artery.

Authors:  S Muzaffar; N Shukla; G D Angelini; J Y Jeremy
Journal:  Thorax       Date:  2005-04       Impact factor: 9.139

Review 8.  Therapeutic approaches using nitric oxide in infants and children.

Authors:  Robin H Steinhorn
Journal:  Free Radic Biol Med       Date:  2011-01-13       Impact factor: 7.376

9.  Update on PPHN: mechanisms and treatment.

Authors:  Jayasree Nair; Satyan Lakshminrusimha
Journal:  Semin Perinatol       Date:  2014-03       Impact factor: 3.300

10.  Reactive oxygen species-reducing strategies improve pulmonary arterial responses to nitric oxide in piglets with chronic hypoxia-induced pulmonary hypertension.

Authors:  Candice D Fike; Anna Dikalova; James C Slaughter; M R Kaplowitz; Y Zhang; Judy L Aschner
Journal:  Antioxid Redox Signal       Date:  2013-01-29       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.